Kura Oncology Inc (KURA.OQ)
16.40USD
20 Apr 2018
-- (--)
$16.40
--
--
--
--
81,760
$24.00
$5.90
Tue, Mar 13 2018
BRIEF-Kura Oncology Inc - Co Entered Into An Amended And Restated Sales Agreement With Cowen And Company
* KURA ONCOLOGY INC - ON MARCH 12, 2018, CO ENTERED INTO AN AMENDED AND RESTATED SALES AGREEMENT WITH COWEN AND COMPANY, LLC - SEC FILING
BRIEF-Kura Oncology Provides Regulatory Update On Tipifarnib
* KURA ONCOLOGY PROVIDES REGULATORY UPDATE ON TIPIFARNIB AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
BRIEF-Kura Oncology files for mixed shelf offering of up to $200 mln - SEC filing
* Kura Oncology Inc - files for mixed shelf offering of up to $200 million - SEC filing Source text:(http://bit.ly/2yNnKBA) Further company coverage:
BRIEF-Kura Oncology Inc entered into amendment to its sales agreement with Cowen and Co
* Kura Oncology Inc - on Nov 9, 2017, co entered into amendment to its sales agreement, dated January 27, 2017 with Cowen and Company LLC -SEC filing
BRIEF-Kura Oncology reports third quarter 2017 financial results
* Kura Oncology reports third quarter 2017 financial results and provides corporate update
BRIEF-KURA ONCOLOGY CONFIRMS PARTIAL RESPONSES OBSERVED IN PATIENTS WITH HRAS MUTANT HNSCC IN TRIAL
* KURA ONCOLOGY LEAD CANDIDATE TIPIFARNIB SHOWS DURABLE ANTI-TUMOR ACTIVITY IN HRAS MUTANT HEAD AND NECK CANCER IN AACR-NCI-EORTC UPDATE
- Your Daily Pharma Scoop: Portola's New Interim Data, Lantheus Announces Promising Data For LMI 1195, Kura Tumbles On Update
- Kura Oncology's (KURA) CEO Troy Wilson on Q4 2017 Results - Earnings Call Transcript
- Kura Oncology: Data Continues To Propel Shares Higher
- Kura Oncology (KURA) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
- ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk
- Biotech Forum Daily Digest For February 12th